With the astounding success of Radiohead's bold gambit earlier this month to market and sell their new album online (at least initially), Billboard is now reporting that the band will embark on a large-scale tour next year. Although this is a typical move in the music industry, and certainly "normal" band news, it has me wondering whether a large-scale tour by Radiohead will be or can be as industry changing as the release of In Rainbows.
Undoubtedly, a new worldwide tour by Radiohead will look very similar to past tours the band has taken around the globe, in particular their 2001 and 2003 global expeditions. Billboard reports that when the band toured last year it was "almost for creative reasons, definitely not for financial reasons." The tour was limited to few European and North American venues. With In Rainbows, the band has followed that trend into the selling of their album, allowing fans to set the price, which apparently averaged around £4 ($8).
A worldwide tour in the scope of past Radiohead tours and other contemporary efforts by other artists is certainly not one for "creative reasons," since the amount of travel would be overwhelming. Financially, such an endeavor would be expensive, but not simply in economic terms. Thom Yorke, the band's front man has been gone on record in the past "over the effects of touring on climate change." For a band as socially conscious as Radiohead have been with their music, such a concern is not surprising, but the report does not indicate the band looks to miss out on engaging the music with fans.
In any case, the answer to my question is that there is no answer, at least not yet. It is unfortunate that preliminary plans are not any more decisive, but albums and tours are the pillars around which the music industry is built. If one can be shaken up so fundamentally, then why can't the other one? The real question is how can a tour be shaken up?
Last updated: February 12, 2012: 09:05 PM
Hot Stocks
DailyFinance Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
Benzinga Headlines
- Michigan Consumer Sentiment Index Drops
- Don't Bank on Barclays
- GSV Capital Punished for Expanding Facebook Investment
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
TheFlyOnTheWall.com Headlines
- Milestone Aviation Group signs contract for three S-92 helicopters
- Greek parliament approves austerity bill, Reuters reports
- Xstrata shareholders want Glencore offer above three shares, Telegraph says
- France Telecom pursuing greater interest in Egypt's Mobinil, Bloomberg says
- Arab league to ask U.N. for a peacekeeping force in Syria, WSJ says
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

